[{"company":"Vernalis","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Vernalis"},{"company":"Almac Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 AACR Virtual Annual Meeting II","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Almac Group"},{"company":"Redx Pharma","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$420.0 million","upfrontCash":"$10.0 million","newsHeadline":"Redx Announces New Research Collaboration with Jazz Pharmaceuticals to Discover and Develop Two Targeted Cancer Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Redx Pharma"},{"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cancer Research UK and AstraZeneca\u2019s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"PhoreMost"},{"company":"Domainex","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Expansion of APEIRON Biologics and Domainex Partnership will Advance Cancer Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Domainex"},{"company":"Crescendo Biologics Ltd","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescendo Biologics Expands its Ongoing Collaboration with Takeda","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Crescendo Biologics Ltd"},{"company":"Oxford Biotherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biotherapeutics"},{"company":"Pathios Therapeutics","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$475.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pathios Therapeutics Receives \u00a3350K Funding Reward From Innovate UK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pathios Therapeutics"},{"company":"Aptamer Group","sponsor":"PinotBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aptamer and PinotBio Collaborate on Drug Conjugates for Targeted Drug Delivery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Aptamer Group"},{"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Macomics Macrophage-based Drug Discovery Company, Secures \u00a34.24m Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Macomics"},{"company":"Exscientia","sponsor":"GT Apeiron Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Exscientia"},{"company":"Storm Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$17.0 million","newsHeadline":"Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"company":"F-star Therapeutics","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,367.5 million","upfrontCash":"$17.5 million","newsHeadline":"F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"company":"Dunad Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,324.0 million","upfrontCash":"$24.0 million","newsHeadline":"Dunad Therapeutics Enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Dunad Therapeutics"},{"company":"AstraZeneca","sponsor":"Integral Molecular","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AstraZeneca"},{"company":"Enara Bio","sponsor":"Monash University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Enara Bio"},{"company":"F-star Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$41.0 million","upfrontCash":"$1.0 million","newsHeadline":"F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"F-star Therapeutics"},{"company":"Nodus Oncology","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Launches, Founded by Cumulus Oncology and In Partnership with The Lead Discovery Center, to Focus on Developing First and Best-In-Class Molecules Inhibiting Novel DNA Damage Response Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Nodus Oncology"}]
Details:
The financing will be used to expand and develop Nodus’ portfolio of first-in-class and best in class assets. LDC will act as the drug discovery arm of Nodus and participate in the development of all assets in Nodus’ pipeline.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Cumulus Oncology
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
September 06, 2022
Details:
Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.
Lead Product(s):
Bispecific Antibody
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Takeda Pharmaceutical
Deal Size: $41.0 million
Upfront Cash: $1.0 million
Deal Type: Licensing Agreement
July 20, 2022
Details:
A novel TCR-T cell therapy targeting a cancer-specific antigen presented by monomorphic MR1, an unconventional antigen-presenting molecule that presents metabolites to immune system in context of cancer and infection to overcome the challenge of HLA restricted TCR therapies.
Lead Product(s):
TCR-T Cell Therapy
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Monash University
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 09, 2022
Details:
Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.
Lead Product(s):
Monoclonal Antibodies
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Integral Molecular
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
November 03, 2021
Details:
Under the terms of the agreement, Dunad will apply its tunable and highly selective platform to generate novel covalent and targeted protein degrading small molecule drugs focusing on up to four drug targets agreed with Novartis.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novartis Pharmaceuticals Corporation
Deal Size: $1,324.0 million
Upfront Cash: $24.0 million
Deal Type: Collaboration
November 02, 2021
Details:
Under the terms of the agreement, F-star will grant Janssen, a exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms.
Lead Product(s):
Tetravalent Bispecific Antibodies
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Janssen Pharmaceutical
Deal Size: $1,367.5 million
Upfront Cash: $17.5 million
Deal Type: Licensing Agreement
October 20, 2021
Details:
The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Exelixis
Deal Size: Undisclosed
Upfront Cash: $17.0 million
Deal Type: Collaboration
October 14, 2021
Details:
Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. It is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic.
Lead Product(s):
Macrophage-based Therapeutics
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Caribou Property Limited
Deal Size: $5.8 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 29, 2021
Details:
This expanded collaboration follows the successful design of multiple selective CDK7 compounds. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
GT Apeiron Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
July 21, 2021
Details:
The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.
Lead Product(s):
FL-118-based Drug Conjugate
Therapeutic Area: Oncology
Product Name: FL-118
Highest Development Status: Discovery
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
PinotBio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
June 03, 2021
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
